Loading stock data…
ZNTL
$4.09+0.08 (+2.00%)
Market ClosedLast close May 1
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zentalis Pharmaceuticals, Inc. in the Healthcare sector is trading at $4.09. The stock is currently 41% below its 52-week high of $6.95, remaining 93.8% above its 200-day moving average. Technical signals show oversold RSI of 24 and bearish MACD signal, explaining why ZNTL maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 24) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.09
Potential Upside
5%
Whystock Fair Value$4.29
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a P...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$272.38M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.66
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-63.39%
Volume
Today's trading volume
729,409
Recent News
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) is one of the must-buy small cap stocks to buy. On April 10, Jefferies raised its price target on Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) from $2.50 to $6.00 and left the Hold rating unchanged. This decision came after Zentalis said it had selected the optimal dose of its lead cancer drug azenosertib […]
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone
Zentalis Pharmaceuticals (ZNTL) has drawn fresh attention after selecting a 400 mg once-daily, 5-days-on, 2-days-off dose of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer, based on interim DENALI Part 2a data. See our latest analysis for Zentalis Pharmaceuticals. The recent azenosertib dose selection and other trial updates have coincided with sharp share price momentum, with a 7 day share price return of 151.33% and a year to date share price return of 382.48%, even...
Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon
Zentalis Pharmaceuticals (NASDAQ:ZNTL) executives outlined a strategy centered on advancing its WEE1 inhibitor azenosertib toward potential approval in platinum-resistant ovarian cancer (PROC), emphasizing a targeted approach in patients with high cyclin E1 protein expression. Speaking at a Guggenhe
Mitsui Sumitomo Continues to Build WR Berkley Stake
W.R. Berkley and Navan have just seen some huge insider purchases. have seen some huge insider purchases, and there were some other notable insider purchases as well.
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Progress And Insider Buying
Zentalis Pharmaceuticals (ZNTL) has come into focus after progress in its azenosertib oncology program, including completed enrollment in the Phase 2 DENALI trial, FDA alignment on the Phase 3 ASPENOVA design, and a large insider share purchase. See our latest analysis for Zentalis Pharmaceuticals. The latest clinical milestones and insider buying have coincided with a sharp shift in sentiment, with a 7 day share price return of 172.99% and a 90 day share price return of 130.86%. However, the...